Stanford Cancer Institute
Stanford MEDICINE

Stanford Cancer Institute

Genitourinary

Version Date:
November 4, 2022

Prostate

Castration-Resistant (CRPC)

Received prior taxane-based chemotherapy and NHT therapy for castration sensitive locally advanced or metastatic castration resistant/sensitive disease

VAR0220
Phase I XL092 Single-Agent & Combo Therapy in Inoperable Locally Advanced or Metastatic Solid Tumors

PI: Srinivas
Sponsor: Exelixis, Inc.

1st Line Metastatic (Radiation)

PROS0094
Phase II
I-131-1095 RT Combo w/ Enzalutamide in Metastatic Castration-Resistant PrOstate Cancer

PI: Iagaru
Sponsor: Pending

1st Line Metastatic (Medical Oncology)

PROS0117
Phase II Trial of SRF617 in Combination with AB928 (Etrumadenant) and AB122 (Zimberelimab) in Metastatic Castration-Resistant Prostate Cancer

PI: Srinivas
Sponsor: Surface Oncology, Inc.

Received at least 2 approved thereapies for metastatic and/or castration resistant disease

PROS0110
Phase I/II
REGN4336 +/- Cemiplimab in Metastatic Castration Resistant Prostate Cancer

PI: Srinivas
Sponsor: Regeneron Pharmaceuticals, Inc.

2nd Line Metastatic

PROS0115
Phase III
Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy in mCPRC

PI: Srinivas
Sponsor: Exelixis, Inc.

3rd Line Metastatic: Progressed on ADT and Secondary Hormonal Therapy as well as Taxane Unless Inelligle or Declined

PROS0119
Phase I
CC-94676 in Subjects With Metastatic Castration Resistant Prostate Cancer

PI: Srinivas
Sponsor: Celgene Corporation

3rd Line Metastatic

PROS0106
Phase III PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

PI:Aparici
Sponsor: POINT BioPharma USA Inc.

PROS0109
Pilot Study for Optimizing Mental Wellbeing & Heart Health for Black Patients w/ Prostate Cancer

PI: Fan
Sponsor: Stanford University

Rising PSA before and after study:
PROS0100
Phase I
Tolerability/ Palatability of TalityTM Synthetic Meal Replacement in Prostate Cancer

PI: Stafford
Sponsor: Stanford University

KEY

- Pending
- Open for Enrollment
- Observational Study
- Optional Path
- Link — Trial Posting
- Enrollment on Hold
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu